Mark Emalfarb
Impact in
- Biotechnology top 5%
- Enzyme Production and Characterization
- Biomedical Engineering top 10%
- Biofuel production and bioconversion
- Catalysis for Biomass Conversion
Papers in
-
- vaccines and immunoinformatics approaches 2
- Bacillus and Francisella bacterial research 2
- Fungal and yeast genetics research 1
-
- SARS-CoV-2 and COVID-19 Research 2
- Antifungal resistance and susceptibility 1
- Co-authors
- Alexander V. Gusakov (3 shared papers)А. П. Синицын (3 shared papers)Richard P. Burlingame (2 shared papers)О. Н. Окунев (2 shared papers)Boris B. Ustinov (1 shared paper)Jan C. Verdoes (2 shared papers)Peter J. Punt (2 shared papers)Rob Joosten (2 shared papers)
- Journals
- Vaccine (1 paper)Biotechnology and Bioengineering (1 paper)Vaccines (1 paper)Applied Biochemistry and Biotechnology (1 paper)Toxicologic Pathology (1 paper)
- Partner nations
- FinlandRussiaNetherlands
In The Last Decade
Mark Emalfarb
8 papers receiving 350 citations
Peers
Comparison fields: 5 of 47
- Biotechnology 147
- Biomedical Engineering 255
- Molecular Biology 215
- Biomaterials 40
- Nutrition and Dietetics 24
Countries citing papers authored by Mark Emalfarb
This map shows the geographic impact of Mark Emalfarb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Emalfarb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Emalfarb more than expected).
Fields of papers citing papers by Mark Emalfarb
This network shows the impact of papers produced by Mark Emalfarb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Emalfarb. The network helps show where Mark Emalfarb may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Emalfarb, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 169 | |
| 2 | 2011 | 125 | |
| 3 | 2007 | 31 | |
| 4 | 1998 | 12 | |
| 5 | 2022 | 10 | |
| 6 | 2022 | 7 | |
| 7 | 2022 | 5 | |
| 8 | 2023 | 3 |
About Mark Emalfarb
Mark Emalfarb is a scholar working on Molecular Biology, Infectious Diseases, Biomedical Engineering, Biotechnology and Ecology, having authored 8 papers that have together received 362 indexed citations. Recurring topics across this work include Biofuel production and bioconversion (3 papers), Enzyme Production and Characterization (2 papers), vaccines and immunoinformatics approaches (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Bacillus and Francisella bacterial research (2 papers), Antifungal resistance and susceptibility (1 paper), Fungal and yeast genetics research (1 paper) and Microbial Community Ecology and Physiology (1 paper). The work is most often cited by research in Biotechnology (147 citations), Biomedical Engineering (255 citations), Molecular Biology (215 citations), Biomaterials (40 citations) and Nutrition and Dietetics (24 citations). Mark Emalfarb has collaborated with scholars based in Finland, Russia and Netherlands. Frequent co-authors include Alexander V. Gusakov, А. П. Синицын, Richard P. Burlingame, О. Н. Окунев, Boris B. Ustinov, Jan C. Verdoes, Peter J. Punt, Rob Joosten, Jaap Visser and Vivi Joosten. Their work appears in journals such as Vaccine, Biotechnology and Bioengineering, Vaccines, Applied Biochemistry and Biotechnology and Toxicologic Pathology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.